ARQ 621

Drug Profile

ARQ 621

Alternative Names: ARQ-621

Latest Information Update: 04 Apr 2014

Price : $50

At a glance

  • Originator ArQule
  • Class Antineoplastics; Small molecules
  • Mechanism of Action KIF11 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Haematological malignancies; Solid tumours

Most Recent Events

  • 31 Mar 2014 Discontinued - Phase-I for Solid tumours (metastatic disease) in USA before March 2014 (Intravenous)
  • 31 Mar 2014 Discontinued - Phase-I for Haematological malignancies (late-stage disease) in USA before March 2014 (Intravenous)
  • 30 Sep 2011 ArQule completes a phase I trial in Solid tumours (metastatic disease) and Haematological malignancies (late-stage disease) in USA (NCT00825487)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top